On August 2, 2023, JMP Securities analyst Reni Benjamin expressed his outlook on BioAtla (NASDAQ:BCAB), reaffirming a positive Market Outperform rating and setting a new price target of $12. This adjustment marks a decrease from the previous target of $17, which was modified on March 27, 2023.
Taking into account various projections, as of May 11, 2023, the average one-year price target for BioAtla stands at $15.30. Analysts’ forecasts range from a low estimate of $8.08 to a high estimate of $26.25.
Looking ahead, BioAtla is projected to generate an annual revenue of $4 million, while the anticipated annual non-GAAP EPS is forecasted to be -2.84.
It is worth noting that on June 1, 2023, BioAtla’s shares concluded trading at $3.46.
Updated on: 07/12/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
10:00 PM (UTC)
Date:07 December, 2023
There are no analysts data to display
BCAB Stock: Stable Trading Day with Limited Investor Interest
BCAB stock, belonging to the Health Technology sector and Biotechnology industry, had an interesting day of trading on August 2, 2023. Let’s take a closer look at its performance using the information provided by CNN Money.
The stock started the day at the same price as the previous close, opening at $2.88. Throughout the trading session, its price fluctuated within a range of $2.60 to $2.88. This indicates that there was no significant movement in the stock’s price during the day.
The trading volume for BCAB on August 2 was relatively low, with only 4,920 shares being traded. This is significantly lower than the average volume of 509,523 shares over the past three months. The low volume could suggest that there was less interest in trading BCAB stock on this particular day.
BCAB’s market capitalization stood at $138.2 million, indicating the total value of all its outstanding shares. This is a relatively small market cap compared to other companies in the industry.
When it comes to earnings growth, BCAB experienced a positive growth rate of 0.91% in the last year. However, there is no information available regarding its earnings growth for the current year or the next five years. This lack of data makes it difficult to assess the future prospects of BCAB’s earnings.
The revenue growth for BCAB in the previous year was -100.00%, indicating a decline in revenue. This negative growth rate could be a cause for concern for investors, as it suggests a decrease in the company’s financial performance.
The P/E ratio for BCAB is listed as NM, which stands for “Not Meaningful.” This could be due to the fact that BCAB reported negative earnings, resulting in an undefined P/E ratio.
Other valuation metrics, such as price/sales and price/book ratios, are not provided, making it challenging to evaluate BCAB’s performance in relation to its industry peers.
Unfortunately, there is no information available regarding BCAB’s executives, last reporting date, EPS forecast for this quarter, annual revenue, annual profit, or net profit margin. These details would have provided a more comprehensive understanding of BCAB’s financial health and performance.
In conclusion, BCAB stock had a relatively uneventful day of trading on August 2, 2023. The stock’s price remained stable, but the low trading volume suggests limited investor interest. The lack of data regarding earnings growth, valuation metrics, and financial details makes it challenging to assess BCAB’s overall performance and prospects.
BCAB Stock Shows Positive Performance and Analysts Optimism for Bioatla Inc
BCAB stock had a positive performance on August 2, 2023, according to data from CNN Money. There are 6 analysts offering 12-month price forecasts for Bioatla Inc, with a median target of 15.50. The high estimate is 25.00, while the low estimate is 12.00.
The median estimate of 15.50 represents a significant increase of 484.91% from the last price of 2.65. This indicates that the analysts are optimistic about the future performance of BCAB stock.
Furthermore, the current consensus among 6 polled investment analysts is to buy stock in Bioatla Inc. This rating has remained steady since June, when it was unchanged from a buy rating. This suggests that the analysts have maintained a positive outlook on the company’s prospects.
In terms of financial performance, the current quarter earnings per share for BCAB stock is -$0.65. This indicates that the company has incurred a loss in the current quarter. However, the sales for the current quarter are reported as $0.00, suggesting that the company has not generated any revenue during this period.
The reporting date for the current quarter’s earnings is listed as TBD (to be determined).
Overall, based on the analysts’ forecasts and the consensus rating, BCAB stock appears to have a positive outlook. However, investors should consider the current quarter’s financial performance and monitor the upcoming earnings report for a more comprehensive assessment of the company’s financial health.